VivoSeq
Oncology

Bone Sarcoma

26

Pipeline Programs↗

7

Active Trials↗

12

Companies Involved↗

Bone Sarcoma is an emerging landscape with 26 programs across 12 companies. The most active players are Amring, Pfizer, Bayer. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

11/100

Mech. Concentration

15/100

Completion Rate

80/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Amring

1 program

Phase 1Pfizer logo

Pfizer

3 programs

Phase 2Bayer logo

Bayer

2 programs

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Roche logo

Roche

1 program

Phase 2B

Bukwang Pharmaceutical

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

23 of 27 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody27%Protein / enzyme14%Cell therapy14%

Small molecule leads; the ring shows all 27 classified programs, each share of the total. Modality classified for 100% of 27 pipeline programs.

Analysis

Trial Status

15

clinical trials

Recruiting6 · 40%
Completed4 · 27%
Unknown status3 · 20%
Active, not recruiting1 · 7%
Terminated1 · 7%

Clinical Trials

Trial Activity

15 trials

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06474676·40 enrolled
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
Recruiting·CCentre Leon Berard·Phase 2·NCT04698785·36 enrolled
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Recruiting·CCentre Leon Berard·N/A·NCT04055220·168 enrolled
Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse
Recruiting·—·Phase 2·NCT04758000·67 enrolled
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05621668·40 enrolled
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07193550·70 enrolled
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Active, not recruiting·UUNICANCER·Phase 2·NCT02389244·163 enrolled
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Completed·NNorthwestern University·Phase 2·NCT02357810·178 enrolled
European Study in Bone Sarcoma Patients Over 40 Years
Completed·IItalian Sarcoma Group·N/A·NCT02986503·100 enrolled
Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Completed·WWashington University School of Medicine·Phase 2·NCT00802880·80 enrolled
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT03277924·197 enrolled
Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
Terminated·UUniversity College, London·Phase 2·NCT02022358·34 enrolled
Efficacy of Tranexamic Acid in Preventing Post Operative Blood Loss in Bone Sarcoma Patient
Unknown status·SShaukat Khanum Memorial Cancer Hospital & Research Centre·Phase 1·NCT05427513·42 enrolled
Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study
Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT03539172·61 enrolled
TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss
Unknown status·PPeking University People's Hospital·Phase 1/2·NCT04690725·29 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)